M H Noe1, S K Grewal1, D B Shin1,2, A Ogdie2,3, J Takeshita1,2, J M Gelfand1,2. 1. Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA. 2. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA. 3. Division of Rheumatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Abstract
BACKGROUND: The hepatitis C virus (HCV) is a major cause of global morbidity and mortality, with conflicting evidence regarding a possible association with psoriasis. OBJECTIVE: To determine the prevalence of HCV in psoriasis patients, compared to controls, and to determine the incidence of hepatic decompensation in HCV+ psoriasis patients compared to HCV+ controls. METHODS: Cross-sectional and cohort studies were conducted in The Health Improvement Network (THIN). RESULTS: In fully adjusted models, a statistically significant increase in prevalence was seen in the adults with psoriasis (OR: 1.24, 95% CI 1.10-1.40). A "dose-response" of HCV prevalence with increasing psoriasis severity was not observed. HCV+ patients with psoriasis had a non-statistically significant increased incidence of hepatic decompensation compared to HCV+ individuals without psoriasis (aHR: 1.58, 95% CI: 0.90-2.77). The risk was highest and statistically significant, in those with moderate-to-severe psoriasis (aHR: 21.51, 95% CI: 7.58-61.03). CONCLUSIONS: These results demonstrate a higher prevalence of HCV in adults with psoriasis and a higher rate of hepatic decompensation in HCV+ individuals with moderate-severe psoriasis.
BACKGROUND: The hepatitis C virus (HCV) is a major cause of global morbidity and mortality, with conflicting evidence regarding a possible association with psoriasis. OBJECTIVE: To determine the prevalence of HCV in psoriasispatients, compared to controls, and to determine the incidence of hepatic decompensation in HCV+ psoriasispatients compared to HCV+ controls. METHODS: Cross-sectional and cohort studies were conducted in The Health Improvement Network (THIN). RESULTS: In fully adjusted models, a statistically significant increase in prevalence was seen in the adults with psoriasis (OR: 1.24, 95% CI 1.10-1.40). A "dose-response" of HCV prevalence with increasing psoriasis severity was not observed. HCV+ patients with psoriasis had a non-statistically significant increased incidence of hepatic decompensation compared to HCV+ individuals without psoriasis (aHR: 1.58, 95% CI: 0.90-2.77). The risk was highest and statistically significant, in those with moderate-to-severe psoriasis (aHR: 21.51, 95% CI: 7.58-61.03). CONCLUSIONS: These results demonstrate a higher prevalence of HCV in adults with psoriasis and a higher rate of hepatic decompensation in HCV+ individuals with moderate-severe psoriasis.
Authors: Marc Bourlière; Jean-Pierre Bronowicki; Victor de Ledinghen; Christophe Hézode; Fabien Zoulim; Philippe Mathurin; Albert Tran; Dominique G Larrey; Vlad Ratziu; Laurent Alric; Robert H Hyland; Deyuan Jiang; Brian Doehle; Phillip S Pang; William T Symonds; G Mani Subramanian; John G McHutchison; Patrick Marcellin; François Habersetzer; Dominique Guyader; Jean-Didier Grangé; Véronique Loustaud-Ratti; Lawrence Serfaty; Sophie Metivier; Vincent Leroy; Armand Abergel; Stanislas Pol Journal: Lancet Infect Dis Date: 2015-03-13 Impact factor: 25.071
Authors: Danilo Leite Andrade; Maria de Fatima Paim de Oliveira; Teodoro Felipe Pereira de Souza; Rafaela Araujo Lima; Ednaldo Andrade Bomfim; Vitoria Regina Pedreira de Almeida Rêgo; Raymundo Paraná; Maria Isabel Schinoni Journal: Acta Gastroenterol Latinoam Date: 2012-12
Authors: Howa Yeung; Junko Takeshita; Nehal N Mehta; Stephen E Kimmel; Alexis Ogdie; David J Margolis; Daniel B Shin; Rosemary Attor; Andrea B Troxel; Joel M Gelfand Journal: JAMA Dermatol Date: 2013-10 Impact factor: 10.282
Authors: Alexis Ogdie; Sungat K Grewal; Megan H Noe; Daniel B Shin; Junko Takeshita; Zelma C Chiesa Fuxench; Rotonya M Carr; Joel M Gelfand Journal: J Invest Dermatol Date: 2017-11-02 Impact factor: 8.551
Authors: Yong Liu; Sheng Nan Cui; Meng Yao Duan; Zhi Li Dou; Yi Zhen Li; Yi Xing Liu; Ye Xia; Jia Wei Zhang; Xiao Ning Yan; Dong Ran Han Journal: Virol J Date: 2021-07-02 Impact factor: 4.099